close
close
awsum

Roche co-led the Schiffbruch with Hoffnungsträger – Einschätzung for Labor Studies

Neon
Roche co-led the Schiffbruch with Hoffnungsträger – Einschätzung for Labor Studies

AboEinschätzung zur Lungenkrebsstudie

Roche ran Schiffbruch together with Hoffnungsträger

Wirkstoff Tiragolumab did not produce significant results in one of the Phase-III Studies of Lungenkrebs Patienten. It is a fact that Roche benefits from the Übernahme of the USA-Unternehmens Poseida Therapeutics.

Rupen Boyadjian
Roche co-led the Schiffbruch with Hoffnungsträger – Einschätzung for Labor Studies

This is no old Good, it’s a Schlappe’s open hat with Roche’s Immunotherapy Tiragolumab.

Image: Zvg/Roche

A major education program from Roche has been halted once again. Antibody Tiragolumab did not come into contact with the Patients’ Leben at all, but it did not reliably come into contact with the Roche Immunotherapy Organization. The Resultat hatte sich vorherigen Rückschlägen abgezeichnet.

Related Posts